Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866) Fundamentals 2026 — P/E 18.2x, Revenue Analysis | SniperIQ
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥8.5B, trading at ¥5.09 on the SHH. This SniperIQ fundamentals page covers Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's valuation (P/E 18.2x, P/B 1.0x), profitability (net margin 2.9%), revenue (¥15.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's market cap?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866) has a market capitalization of approximately ¥8.5B, trading at ¥5.09 on the SHH. Market cap moves with the live share price.
What is Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's P/E ratio?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's trailing twelve-month P/E ratio is 18.2x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Star Lake Bioscience Co., Inc.Zhaoqing Guangdong?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong runs a net profit margin of 2.9%, a gross margin of 12.9%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Star Lake Bioscience Co., Inc.Zhaoqing Guangdong generate?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong reported revenue of ¥15.9B for fiscal year 2025, with net income of ¥979M and earnings per share (EPS) of 0.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Star Lake Bioscience Co., Inc.Zhaoqing Guangdong pay a dividend?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong offers a trailing dividend yield of about 7.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Star Lake Bioscience Co., Inc.Zhaoqing Guangdong financially healthy?
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong carries a debt-to-equity ratio of 0.67x and a current ratio of 0.97x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Star Lake Bioscience Co., Inc.Zhaoqing Guangdong a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866) the key facts are: market cap ¥8.5B, P/E 18.2x, revenue ¥15.9B, 52-week range 4.26-8.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's full fundamentals live
Get Star Lake Bioscience Co., Inc.Zhaoqing Guangdong's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.